Targeted drugs for non-mutated ovarian cancer are generally commonly used anti-angiogenic drugs, such as bevacizumab, and small molecule anti-angiogenic drugs such as tyrosine kinase inhibitors. Bevacizumab belongs to targeted drugs, which can cut off the oxygen and nutrition supply of the tumor, effectively inhibit the growth of tumor blood vessels, and turn the surviving tumor cells to normal, with less effect on normal cells. Patients with poor physical condition and intolerance to chemotherapy can be treated with Bevacizumab targeted therapy. Long-term use of Bevacizumab after surgical treatment, radiotherapy and chemotherapy can reduce the rate of disease recurrence and metastasis. The risk of gastrointestinal perforation and gallbladder perforation may be increased when patients are treated with bevacizumab, and the risk of bleeding related to the tumor may also be increased, in addition, the risk of arterial thromboembolism as well as high blood pressure and other diseases will be increased, so make sure to use it under the guidance of a doctor.